USPTO 2015–2025 USPTO PatentsView US Corporation

ALCRESTA THERAPEUTICS, INC.

USPTO PatentsView assignee record — 22 granted patents across 12 technology areas, active 2017–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A23L (FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF).

22
Total patents granted
12
CPC technology areas
23.1
Avg claims per patent
+240%
5-year filing velocity

Portfolio overview

ALCRESTA THERAPEUTICS, INC. has been granted 22 US utility patents between 2017 and 2024, placing ALCRESTA THERAPEUTICS, INC. at rank #13,282 across all assignees tracked by PlainPatent. This portfolio spans 12 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.1 claims per patent with primary concentration in A23L (FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF). As a US Corporation, ALCRESTA THERAPEUTICS, INC. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 47.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 17 grants, compared with 5 in the 2015–2019 window — a +240% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. ALCRESTA THERAPEUTICS, INC.'s 23.1 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 12 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ALCRESTA THERAPEUTICS, INC. against peers pursuing similar technology classes.

How does ALCRESTA compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows ALCRESTA holds 22 patents — placing it at rank #13,282 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2017–2024

0246810 201720192020202120222024 9
USPTO utility patent grants by year · 2017–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
ALCRESTA THERAPEUTICS, INC. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 4 18.2%
2019 1 4.5%
2020 3 13.6%
2021 3 13.6%
2022 2 9.1%
2024 9 40.9%

Which technologies does ALCRESTA THERAPEUTICS, INC. patent most?

Top 12 of 12 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating

Where it ranks

Overall rank by patents

#13,282

Across all tracked assignees

Innovation Score

47.4 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does ALCRESTA THERAPEUTICS, INC. hold?
ALCRESTA THERAPEUTICS, INC. holds 22 US granted patents filed between 2017 and 2024, spanning 12 technology areas.
What is ALCRESTA THERAPEUTICS, INC.'s Innovation Score?
ALCRESTA THERAPEUTICS, INC. has an Innovation Score of 47.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does ALCRESTA THERAPEUTICS, INC. focus on?
ALCRESTA THERAPEUTICS, INC.'s top technology area is A23L (FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF) with 20 patents. The company has filed patents in 12 CPC subclasses total.
Is ALCRESTA THERAPEUTICS, INC.'s patent filing rate increasing or decreasing?
ALCRESTA THERAPEUTICS, INC.'s recent filing velocity is +240% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for ALCRESTA THERAPEUTICS, INC.'s patents?
ALCRESTA THERAPEUTICS, INC.'s patents average 23.1 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the ALCRESTA THERAPEUTICS, INC. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope